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in Human Gut Microbiota Dysbiosis? 
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Background and Objectives: Novel probiotics and prebiotics designed to modulate 
the gut microbiota for improving health outcomes are in demand as the importance of 
the gut microbiota in human health is revealed. A review of the scientific literature 
regarding the current knowledge and novel species and novel oligosaccharides for the 
treatment of dysbiosis-associated diseases has been carried out due to their growing 
interest. 
 
Results and Conclusions: The regulations governing introduction of novel probiotics 
and prebiotics vary by geographical region. Novel foods and foods with health claims 
fall under specific regulations in several countries. In European Union (EU), safety is 
assessed by novel food approval process and by the European Food Safety Authority 
(EFSA) established Quantitative Presumption of Safety (QPS) system for bacteria and 
other biologicals. Any messages on health benefits are covered by the European 
Regulation on Health Claims (ERHC), also assessed by EFSA. Examples of recent 
novel probiotics in EU include Clostridium butyricum, and Bacteroides xylanisolvens 
and examples of novel prebiotics include human milk oligosaccharides such as Lacto-
N-neotetraose. Yacon root is an example on a previously novel prebiotic food which is 
allowed due to the reported existing cultivation and use in EU prior to the novel food 
regulation. Potential future candidates include further human milk oligosaccharides 
and bacteria such Faecalibacterium prausnitzii and Akkermasia muciniphila. 
Increasing knowledge on human intestinal microbiota and microbiota development 
enables the design of new more specific and hitherto unknown probiotics and 
prebiotics. Also understanding the microbe and microbe host interactions facilitates 
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Research interest in novel probiotics and 
prebiotics has increased rapidly due to the fast-paced 
discoveries in both composition and activity of 
human microbiome and their impact on health. Tools 
to manipulate gut microbiota and thereby improve 
both short-term and long-term health outcomes are 
also developing fast. Some of the current probiotics 
and prebiotics have been used for decades, but novel 
strains and components are identified for unique 
outcomes and are therefore expected to emerge 
rapidly [1]. The challenges for novel probiotic 
bacteria and prebiotics remain in the varying 
regulatory systems in different parts of the world. In 
Europe, two important legislative controls regulate 




uropean market. These include the safety assessment 
along with the recently revised Novel Food 
Regulation [2] and the health benefit assessment 
according to the Regulation on Health Claims [3]. An 
assessment of the current safety work in Europe and 
Health Claims in European Union will attempt to 
uncover the road to the market of novel probiotics 
and prebiotics with examples of their regulatory 
assessment and resulting decisions available until 
now. 
 
2. Human intestinal microbiota 
 
The human microbiota is a dynamic ecosystem 
established after birth and composed for all the 
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microorganisms living in human surface or inside our 
body in naturally symbiotic relationship with him [4].  
The intestinal microbiota has the highest 
microbial diversity of the human body, with more 
than 1000 different bacterial species belonging in 
their majority to relatively few bacterial phyla: 
Firmicutes, Bacteroidetes, Actinobacteria, and 
Proteobacteria [5, 6]. Although there is an increasing 
knowledge about the kinds of organisms, their 
abundance and taxonomical distribution in various 
parts of the human body; we still have to understand 
much better how they interact with each other or 





Figure 1. Changes in intestinal microbiota during life (adapted from Isolauri et al., [61]). Maternal microbiota changes between 
the first and third trimester during pregnancy and the first months postpartum, may be to promote transfer of specific strains to the 
infant [3]. During the first months of life the main bacterial groups are conditioned by the way of delivery and the food 
consumption pattern. Gradually, with the introduction of solid food, the bacterial diversity is increasing to rise the adult pattern 
after several years. 
 
 
The establishment of our microbiota (Figure 1) 
begins already before birth by microbial contact 
through placenta and amniotic fluid [8] and seems to 
be greatly influenced by the mode of delivery 
through perineal, vaginal, and faecal microbiota 
inoculum by normal delivery or skin inoculum by 
caesarean section [9].  
Differences in the initial inoculum are maintained 
along the next years, being detected even at the age 
of seven years [10], which might have an impact on 
infant health. After birth, the neonatal intestine 
becomes rapidly colonized by maternal and environ-
mental bacteria and colonization continues during 
lactation increasing complexity and microbial diver-
sity [11].  
Another great influencing factor for the initial 
intestinal microbiota is the infant feeding. Breast 





 viable bacterial per mL, prebiotic nutrients and 
bioactive components, playing an important role in 
the establishment of the neonatal microbiota [12, 13]. 
Infants that are exclusively breast-fed in harbour a 
microbiota dominated by Bifidobacteria and Lacto-
bacillus, while exclusively formula-fed infants host a 
more diverse microbiota with increased abundance of 
Escherichia coli, Clostridia, and Bacteroides [4]. This 
differences might be caused not only for bacterial 
composition of human milk, but also for the presence 
of human milk oligosaccharides, a diverse family of 
unconjugated glycans with a prebiotic role that are 
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highly abundant in human milk and absent in infant 
formulas [4]. 
Solid food introduction and weaning increase the 
diversity of the microbiome and microbiota function-
ally maturates by a decrease in the relative abundance 
of genes involved in the degradation lactate 
utilization and towards enrichment of genes involved 
in the degradation of carbohydrates [6,11].  
The intestinal microbiota closely resembles the 
diverse adult-like composition at the age of three 
years with high levels of Bacteroides and Clostrid-
ium, changes in Lactobacillus population and 
reducing Bifidobacterium levels [4] 
Each human individual reaches a homeostatic 
composition, remaining relatively stable during most 
of a healthy adult‟s life [14,15]. Although each 
individual has a specific microbial composition at the 
species level [16], the overall phylogenetic profile 
might be categorized into different host-microbial 
ecosystems dominated by several clades with broad 
prevalence and relatively abundant carriage patterns 
that could have functional differences [16,17], doing 
that their host might respond differently to diet or 
drug intake. Defining normal healthy microbiota is 
impossible due to the great inter-individual variation 
among the species of microbes present at different 
body locations, together with variations in microbiota 
related with age, geographic area, genetic back-
ground, mode of delivery, breast-feeding, age, diet, 
hormonal cycles, travel, health status, and medical 
treatments of the host [5,14,18]. 
The microbiota has a profound impact on its host 
by providing a competitive barrier against invading 
pathogens, utilizing undigested food components and 
producing essential metabolites, modulating immune 
responses and immune system development, and 
stimulating intestinal maturation [12,14]. 
Microbial richness, intended as high bacterial 
diversity, is usually considered an indicator of a 
healthy status and makes the host less prone to a 
number of diseases [7]. Low richness is associated 
with several life-style related non-communicable 
diseases such as obesity, metabolic syndrome, 
immune-related, and inflammatory diseases [5]. The 
number and diversity of bacterial species within an 
individual‟s gastrointestinal tract remain relatively 
constant throughout life, as mentioned previously, 
but it is possible to stimulate the proliferation of 
specific microorganisms with beneficial health 
effects by manipulating the host diet [19]. 
 
3. Dysbiosis and diseases 
 
Dysbiosis or dysbacteriosis is defined as a pertu-
rbation in the microbiota composition, with a 
decrease in the relative numbers of beneficial 
microbes and a thrive of harmful microbes in the 
intestinal tract [20]. Any defined imbalance between 
protective and harmful bacteria may have the ability 
to promote disease susceptibility and/or progression 
of a disease. Therefore, it is important to identify 
healthy microbiota development and the factors that 
cause deviations (Figure 2). 
However, the distinction between beneficial and 
harmful bacteria is often not clear. It is important to 
consider that the effect of an intestinal micro-
organisms on the host and its pathogenic potential is 
also dependent on the specific circumstance (host 
state, genotype, diet, and lifestyle), meaning that 
microorganisms that are normally beneficial or 
commensal can become a potential threat to the host 
when conditions change [20,21]. 
Dysbiosis has been associated with several 
diseases in humans, and dysbiosis may increase the 
risk of diseases. Dysbiosis associated diseases 
include gastrointestinal and systemic problems, 
obesity, allergy and even cardiovascular diseases [1]. 
However is not clear whether dysbiosis is the cause 
of the disease, or whether both are concomitant 
phenomena [20]. Moreover there are multiple reasons 
for dysbiosis such as caesarean delivery, premature 
birth, short breast-feeding, diet, life style, hygiene or 
antibiotic use. 
The successive development of intestinal 
microbiota from perinatal time to childhood and 
adolescence has been reviewed by Rautava et al. 
[22]. It is evident that the healthy individual 
microbial colonization pattern develops already 
during fetal life, and is influenced by the mode of 
delivery and feeding patterns during infancy 
modulating immune and metabolic development. 
Normal succession of microbes may improve infant 
health and reduce the risk of disease in later life. 
After initial succession and development of 
richness and diversity typical to each person, the gut 
microbiome seems to be relatively stable during 
healthy adulthood. But qualitative and quantitative 
alterations, which lead to functional modifications, 
have been reported and associated with a number of 
human diseases [1]. 
The increased risk of obesity and childhood asth-
ma in children born by caesarean section has been 
attributed to the different intestinal colonization 
pattern in these children [4].  
Moreover, breastfeeding or formula feeding could 
impact in microbiota development (Figure 1). It has 
been shown that allergic infants display an abnormal 
“adult-type” Bifidobacterium flora, with high levels 
of Bifidobacterium adolescentis strain instead of the 
typical infant flora dominated by Bifidobacterium 
bifidum and lower total amount of Bifidobacteria 
[23]. 
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Figure 2. Changes in microbiota. Diet could have a great impact changing key populations in microbiota, which may increase the 
susceptibility to some diseases. Moreover, other factors related with life style or diseases like stress or antibiotic consumption 
may have an impact on microbiota. Specific intervention could balance this changes restoring microbiota and their function. 
 
 
Breastfeeding is reported to be on factor 
influencing infant gut colonization and 
Bifidobacterium longum, appears to be the most 
common species found in breast milk. In a Finnish 
study, also Bifidobacterium lactis, one of the most 
commonly used probiotics, was found second most 
common in the milk of the study mothers [24], 
therefore breast milk microbiota and breast milk 
oligosaccharides are factors which direct infant gut 
microbiota development. 
Emerging evidence suggests that variation in the 
microbiome may have a greater role than human 
genome variation in the pathogenesis of obesity given 
its direct interaction with environmental factors [25]. 
It has been suggested that an “obese microbiota” 
has high potential to extract energy from the diet 
[26]. It has been shown that the composition of 
bacteria in the gut differed between lean and obese 
individuals with a high rate of Firmicutes relative to 
Bacteroidetes, but some recent publications have 
contradicted these findings [27]. 
Allergic diseases has increased worldwide in 
recent decades and has been associated with the 
hygiene hypothesis [1] and changes in the life style. 
Alterations in gut microbiota have been reported in 
patients with allergic diseases and also, low bacterial 
diversity in intestinal microbiota during early life is 
associated with an increased risk of allergic disease 
[28,29]. Moreover, some bacterial phylotypes were 
associated with the development of allergy in infants 
as Clostridium, Enterococcus, Escherichia/Shigella, 
Staphylococcus, Faecalibacterium, or Prevotella [30-
32]. The use of probiotics and prebiotic, or the 
combination of both as a synbiotics, may allow an 
adequate modulation of intestinal microbiota and 





A recent review defined probiotics as “live 
microorganisms that, when administered in adequate 
amounts, confer a health benefit on the host” 
supporting the use of this wording in the future. This 
definition includes a wide range of microbes and 
applications, defining probiotics (microbes, viable, 
and health benefits), and makes a difference between 
microbes used for technological purposes such as 
fermentation and those that are used for their health 
benefits [33]. 
The most frequently used bacterial genera are 
lactic bacteria, mainly from the Lactobacillus genus, 
but also Bifidobacterium genus, and other genera are 
also used such as the Enterococcus, Streptococcus, 
bacteria are commonly found in fermented dairy 
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products, human milk, the intestinal tract of healthy 
children or adults, and also from the digestive tract of 
animals and non-fermented food [1]. Moreover, 
probiotics may belong to other bacterial genera and 
even other domains such as Saccharomyces. 
In Europe, European Food Safety Authority 
(EFSA) has not accepted probiotic health claims 
submitted due to stringent human study requirements. 
The mechanism of action of probiotics is strain 
dependent and not always well known, which is one 
of the problems considered by the authorities. The 
lack of sufficient evidence in healthy individuals is 
another reason [18]. In addition, live bacteria may not 
be powerful enough for induce measurable changes 
in healthy individuals which are necessary to obtain 
health claims [35]. Therefore, as proposed by Kumar 
et al. (2015), suitable scientific evidence is needed in 
different areas including genome information, 
antibiotic resistance profile, and selection criteria. 
Clearly defined target population is also [36].  
Probiotic bacteria that are originally isolated from 
human milk are particularly interesting because they 
fulfil the main requirements recommended for human 
probiotics, such as human origin, a history of safe 
prolonged intake by a particularly sensitive 
population (infants), and they are adapted to reside in 
the human digestive tract and to interact with us in 
symbiosis [12]. 
Probiotics benefits are related with their ability to 
modulate intestinal microbiota of the host preventing 
or limiting pathogen colonization by bacteriocins 
and/or other metabolite production [21,37], and their 
improvement of barrier function of intestinal mucosa 
and immune and inflammatory responses of the host 
[38]. Moreover, specific probiotics are able to 
improve digestion by enzyme production as beta-
galactosidase [1,39].  
Several new probiotics have also been invest-
igated and for examples Clostridum butyricum, a 
species previously used in animal feeds, has a long 
history of use in Japan and was recently accepted as a 
novel food in Europe [40]. Similarly, the safety 
evaluation and novel food approval was given by 
EFSA (2015) for heat inactivated Bacteroides 
xylanisolvens [40], but as the cells are not viable the 
product does not confirm to the probiotic definition 
[33]. It remains to be seen how the work on this 
species will progress in the future. Among probiotic 
candidates, Akkermansia  muciniphila and Faecali-
bacterium prausnitzii have raised a lot of interest in 
the area of weight management [41, 42] and the 
potential safety assessment and human studies need 
to be completed.  
Another direction is the use of probiotics to select 
defined mixed populations of faecal or intestinal 
bacteria from healthy subjects. Preparations such as 
„RePOOPulate‟ have been studied already in human 
trials and they have investigated the use of a stool 
substitute preparation. The preparation, which may 
fulfill the requirements of a probiotic, was made from 
purified intestinal bacterial cultures derived from a 
single healthy donor, to treat recurrent Clostridium 
difficile infection [43,44]. 
Instead of fecal transplants, the defined microbial 
populations used to re-populate the intestinal tract 
may offer future solutions to serious intestinal 
dysbiosis problems such as recurrent or chronic 
Clostridium difficile [44]. Taken together, a large 
number of microbial preparations are considered for 




The prebiotic concept refers to non-digestible 
food components which are selectively metabolized 
by intestinal health-promoting bacteria stimulating 
their growth and their activity [21]. But the definition 
of prebiotics changes between different organizations 
depending on parameters related to selectivity, site of 
action, grade of causality or association proved, and 
the requirement of fermentation or metabolism 
[45,46]. Recently, with the aim to clarify the 
prebiotic concept, Bindels et al. (2015), proposed to 
define prebiotic as “a non-digestible compound that, 
through its metabolism by microorganisms in the gut, 
modulates composition and/or activity of the gut 
microbiota, thus conferring a beneficial physiological 
effect on the host” [21]. 
The mechanisms through prebiotics exert their 
benefits are: 1) selective stimulation of the growth 
and/or activity of intestinal bacteria associated with 
health, mainly Lactobacilli and Bifidobacteria [47]; 
and 2) production of short chain fatty acids (SCFAs), 
particularly butyrate, which have antimicrobial 
activity by reduction of intestinal pH and other 
immunological and physiological activities [21]. 
Most of the studies on prebiotics have been 
focused on fructans, such as inulin-type fructans, 
fructooligosaccharides (FOS) galactooligosaccha-
rides (GOS) [47], and lactulose [48]. The location 
where they seems to exert their activity depend of 
their degree of polymerization (DP), acting in 
proximal areas of the colon those with a low DP, and 
in distal areas those with a high DP [49]. 
Several new sources of prebiotics and plants with 
high  fructooligosaccharide content are under 
investigation. For example Agave-derived fructans 
[49, 50], dextran oligosaccharides [27], gluco-
oligosaccharides, xylo-oligosaccharides, gluc-
omannan, and galactoglucomannan oligosaccharides 
and Yacon root from South America are under 
investigation [51,52]. As has been suggested by 
Jakobsdottir and associates (2014), the development 
of future prebiotics should take into account their 
capacity to alter the gut microbiota and SCFA 
profiles; together with their ability to decrease 
systemic inflammation; increase satiety; and reduce 
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6. How probiotics and prebiotics may help? 
6.1. Allergy and immune related diseases 
 
Several studies correlate commensal microorgan-
isms to balanced response of the immune system and 
oral tolerance acquisition. In infants, the establish-
ment of normal microbiota is fundamental for the 
normal development of the immune system. Thus the 
modulation of infant gut microbiota by prebiotics and 
probiotics may have a broad influence on the immune 
response of the host [53]. In particular, dysregulation 
of T helper cell response is associated with allergy 
and autoimmune diseases [54]. 
Probiotics and prebiotics and allergy prevention is 
likely the most studied area in terms of health 
benefits. Specific probiotics or probiotic combin-
ations, given either as a foods or supplements or in 
foods, have been evaluated in randomized double-
blind controlled trials for primary prevention of 
allergic disease in infants. Such trials have been 
conducted using prenatal, post natal or perinatal 
administration of defined probiotic strains and not all 
strains or settings have been successful. The most 
convincing studies have applied perinatal administer-
ation probiotics [55,56]. Recent World Allergy 
Organization (WAO) guidelines suggest that current-
ly available evidence does not have a strong support 
for prevention of allergies by probiotic administ-
ration. However, WAO guideline panel determined 
that there is a likely net benefit from using probiotics 
resulting primarily from prevention of eczema. The 
WAO guideline panel suggests: a) using probiotics in 
pregnant women at high risk for having an allergic 
child; b) using probiotics in women who breastfeed 
infants at high risk of developing allergy; and c) 
using probiotics in infants at high risk of developing 
allergy [55]. 
Previous studies with FOS and GOS revealed low 
evidence in the prevention of eczema, as potential 
specific FOS/GOS combination benefit for infants at 
high risk of allergy [57]. Therefore, further research 
is required to document this effect in different 
populations. Inside this new kind of prebiotics, 
Agave-derived fructans increase expression of 
FOXP3 transcription factor, which may influence 
reported imbalances of T helper cell response [50]. 
 
6.2. Obesity and metabolic syndrome 
 
The number of cases of obesity and metabolic 
syndrome (characterized by obesity, hyperlipidemia, 
hypertension, insulin resistance, and type 2-diabetes) 
are doubled worldwide since 1980 [26,58]. Although 
the major cause of obesity is excessive energy intake 
and reduced energy expenditure, other factors 
contribute to the onset of obesity and its associated 
disorders. Among this factors which are able to 
impact the host response to nutrients, the gut 
microbiota represents an important one [58]. 
Development of overweight and obesity has been 
associated with early variations in microbiota 
development including both richness and diversity of 
microbiota [59]. Differences in microbiota have been 
reported in both pregnant women and their infants 
later gaining weight and becoming obese, being 
suggested that in breast-fed infants low levels of 
Bifidobacteria may predict later overweight and 
weight gain [60,61]. Therefore, the use of probiotics 
containing Bifidobacterium and Lactobacillus to 
ameliorate obesity and associated metabolic disorders 
has been shown to exert beneficial effects [62]. 
Obesity and high body weight can be altered by 
the consumption of dietary fibres not only through 
their satiating abilities and fat-fibre complex 
formation, but also by a SCFA-mediated physiol-
ogical effect which are thought to influence satiety 
and energy intake [26,27]. Moreover this effect is 
coupled with microbiota modulation and commonly 
associated with a reduction in body weight, body fat 
and adipocyte size [62].  
Recent studies demonstrate prebiotic potential of 
dextran oligosaccharides and xylooligosaccharides in 
increasing Bifidobacterium spp. and SCFA 
concentrations in obese subjects [27,51], who has 
been reported to have low number of Bifidobacterium 
[63]. Moreover, a recent review suggest that specific 
prebiotics may help modulating subjective satiety, 
reducing total energy consumption, reducing ghrelin 
concentration and reducing body weight in long 
duration trials, but future studies are necessary [19]. 
In obese patients, a recent study report changes in 
microbiota after caloric restriction and intervention 
with a mix of lactic acid bacteria, showing an 
increase in Bifidobacteria, Akkermansia and 
Faecalibacterium prausnitzii [41]. Further research 
with the aim to obtain more clinical evidence will be 
of great interest to guide modification of the 
microbiota by probiotics and prebiotics. 
 
7. Regulatory aspects 
 
Novel foods and ingredients are regulated in a 
different ways in different countries. The majority of 
evaluations systems are based on a risk or safety 
assessment reviews and most regulations require both 
notification and approval by a regulatory authority. 
Lists of approved novel food decisions are 
maintained by regulators and are made publicly 
available for instance in EU and Canada. 
In general, safety assessment of new or novel 
probiotics and prebiotics is required worldwide. 
Regulations in European Union consider new 
probiotics from two different standpoints, safety and 
health benefits for health claims. Safety is very much 
directed according to the EFSA following regulation 
on novel foods (2015) and regulation on health 
claims [2]. Novel foods, i.e. foods and food 
components of processes not used in Europe prior to 
1997 must undergo safety assessment prior to 
entering the market. A new probiotic may fall into 
two safety assessment categories as some microbial
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Figure 3. Differences between novel probiotic and prebiotic safety assessment in European Union (foods not previously 
consumed to a significant degree, and evaluation for safety either as live microbes or other novel components) and probiotics and 
prebiotic with health claims (evaluated for efficacy; adapted from Kumar et al., [36]). 
 
species have been assessed by the EFSA as Qualified 
Presumption of Safety (QPS) and do not require an  
extended safety assessment [40]. For example, 
bacteria isolated from human milk, species like 
Lactobacillus gasseri, Lactobacillus salivarius, 
Lactobacillus reuteri, Lactobacillus fermentum or 
Biffidobacterum breve are considered to have 
probiotic potential and enjoy the QPS status. Others, 
not belonging to the QPS status species need to be 
evaluated according to the new novel food regulation.  
All probiotics, if a probiotic status is desired, need 
to be assessed for health effects in addition to safety, 
and this requires a number of human studies. The 
overlap of the three assessment systems is described 
in Figure 3. Apart from the QPS system, similar 
requirements of safety assessment are placed also on 
novel prebiotics. When considering other countries, 
Health Canada assesses the safety of all genetically-
modified and other novel foods proposed for sale in 
Canada and also publishes a list of decision 
concerning novel foods and ingredients. 
It is important also to consider the previous use of 
a novel probiotic or prebiotic worldwide and the 
newly revised European novel food regulation takes 
into consideration the "history of use" of new foods 




Taken together, the area of new probiotics and 
prebiotics is developing rapidly and benefits from 
intestinal microbiota research and new ways of 
dietary modulating microbiota development and 
activity. The expanding database on both mechan-
isms of action and clinical demonstrations in the area 
uncovers new possibilities of reducing the risk of 
both human and animal diseases by microbiota 
modulation. Human milk is an example of a bioactive 
food which contains both microbial and oligo-
saccharide components which have potential in 
probiotic and prebiotic use. Understanding the 
mechanisms of action of these components provides 
new means of nutritional treatment and prevention 
modalities which will be able to improve human 
health. 
In the future, more specific microbes and 
microbial combinations are likely to be introduced 
and the same applies also to new prebiotic 
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